Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 6/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.38 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.35 |
| ▸ | CTSA | P10619 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6202690 | 0.91 | CRHR1 (0.46) | CRHR1TLR7ALDH1A1 | |
| SCHEMBL7478304 | 0.81 | CRHR1 (0.41) | CRHR1TLR7KCNH3CTSAKCNH2 | |
| SCHEMBL5440450 | 0.81 | CRHR1 (0.60) | CRHR1 | |
| SCHEMBL6203447 | 0.80 | TLR7 (0.38) | CRHR1TLR7ALDH1A1POLB | |
| SCHEMBL7477860 | 0.80 | CRHR1 (0.53) | CRHR1KCNH3CTSA | |
| SCHEMBL7119050 | 0.78 | CRHR1 (0.48) | CRHR1TLR7 | |
| SCHEMBL6203899 | 0.77 | TLR7 (0.36) | CRHR1TLR7ALDH1A1POLB | |
| SCHEMBL6204026 | 0.76 | CRHR1 (0.41) | CRHR1 | |
| SCHEMBL6203035 | 0.75 | CRHR1 (0.51) | CRHR1TLR7 | |
| SCHEMBL7472049 | 0.75 | CRHR1 (0.56) | CRHR1TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554258-A1 | 5-SUBSTITUTED-2-ARYLPYRAZINES AS MODULATORS OF CRF RECEPTORS | NEUROGEN CORPORATION (US) | 2005-07-20 | — | — | EP | claimed |
| WO-2004018437-A1 | 5-SUBSTITUTED-2-ARYLPYRAZINES AS MODULATORS OF CRF RECEPTORS | NEUROGEN CORPORATION (US) | 2004-03-04 | — | — | WO | claimed |